Metabolomic Analysis of Lung Cancer

Status Completed

Clinical Trial Summary

The purpose of this study is to learn more about the metabolic properties of lung cancer cells.

Clinical Trial Description

It has long been known that cancer cells absorb and break down substances in the body differently than healthy, non-cancer cells. This process of absorbing and breaking down substances is known as metabolism and is increased in cancer cells. Recent research suggests that this increased metabolic activity makes it easier for cancer cells to multiply. The objective of the study is to characterize the metabolism of glucose by lung tumors by serum metabolite analysis, using a variant of glucose (sugar) which makes up 1% of glucose in nature. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00263731
Study type	Observational
Source	University of Louisville
Contact
Status	Completed
Phase
Start date	December 2005
Completion date	September 24, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04486833` - Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib	Phase 1/Phase 2
Terminated	`NCT00321308` - Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer	Phase 2
Completed	`NCT00190840` - A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer	Phase 2
Terminated	`NCT01441128` - -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer	Phase 1
Recruiting	`NCT05358249` - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	Phase 1/Phase 2
Terminated	`NCT02961283` - Study of ASN003 in Subjects With Advanced Solid Tumors	Phase 1
Recruiting	`NCT00973310` - Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer	Phase 2
Completed	`NCT00385996` - Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer	Phase 2
Terminated	`NCT02775006` - Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma	Phase 3
Completed	`NCT03232593` - A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Terminated	`NCT02590003` - Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer	Phase 2
Terminated	`NCT01514864` - Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation	Phase 2
Completed	`NCT00070629` - CPG 7909 Injection in Non-Small Cell Lung Cancer	Phase 2
Completed	`NCT02079636` - A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)	Phase 1
Terminated	`NCT01115803` - A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors	Phase 1
Completed	`NCT01079520` - Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) Versus Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer (NSCLC)	N/A
Completed	`NCT00861627` - Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation	Phase 2
Completed	`NCT00923884` - Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
Recruiting	`NCT04389632` - A Study of SGN-B6A in Advanced Solid Tumors	Phase 1
Terminated	`NCT03603652` - NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung	N/A